Dominic D'Agostino

Standard American diet produces of like a GKI of 50, 40 or 50.

So simply the guidelines are one to two, but I think that's too strict.

Achieving a glucose ketone index of one to four.

is the basis of the therapy, and that sets the stage for other modalities to work.

For example, you could have, you want to then target glucose and glutamine with various drugs.

If we're going to talk about anti-glycolytic drugs, metformin.

We've done quite a bit of research with metformin, and I think that's a great molecule to

could be a synergizer.

I also think of that as a redox, and I'll come to that.

No, it's not gonna cure it.

So we're talking about the standard of care does nothing.

We're talking about- Life extension.

Yeah, we're talking about doubling survival, tripling, and then as we learn more.

So the ketone metabolic therapy framework for GBM is like the first document in a series of documents that will ultimately be, version number three will be using AI platforms to like decode the genetics

Yeah, those studies are ongoing now.

Jethro Hugh at UCLA just published a study at UCLA showing improved metrics of survival and increased quality of life and different, and I didn't get a chance to, it just came out, a paper just came out.

So that research is ongoing.

I'd say there's at least a half dozen clinical trials in progress now.

And there's problems associated with those clinical trials that I could get into that prevents us from getting to the question.

So the way to do the clinical trial, which has not been done yet, is to achieve and maintain a glucose ketone index of one to four.